Interactions between Tryptophan Metabolism, the Gut Microbiome and the Immune System as Potential Drivers of Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Diseases
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing and therefore is its burden of disease as NALFD is a risk factor for cirrhosis and is associated with other metabolic conditions such as type II diabetes, obesity, dyslipidaemia and atherosclerosis. Linking these cardiometabolic diseases is a state of low-grade inflammation, with higher cytokines and c-reactive protein levels found in individuals with NAFLD, obesity and type II diabetes. A possible therapeutic target to decrease this state of low-grade inflammation is the metabolism of the essential amino-acid tryptophan. Its three main metabolic pathways (kynurenine pathway, indole pathway and serotonin/melatonin pathway) result in metabolites such as kynurenic acid, xanturenic acid, indole-3-propionic acid and serotonin/melatonin. The kynurenine pathway is regulated by indoleamine 2,3-dioxygenase (IDO), an enzyme that is upregulated by pro-inflammatory molecules such as INF, IL-6 and LPS. Higher activity of IDO is associated with increased inflammation and fibrosis in NAFLD, as well with increased glucose levels, obesity and atherosclerosis. On the other hand, increased concentrations of the indole pathway metabolites, regulated by the gut microbiome, seem to result in more favorable outcomes. This narrative review summarizes the interactions between tryptophan metabolism, the gut microbiome and the immune system as potential drivers of cardiometabolic diseases in NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239 · cited 1×
“Histologically, NAFLD can be divided into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), the latter increasing the risk for progression to cirrhosis [4] and hepatocellular carcinoma [5].”
BackgroundEslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis
Yano, J. M., Yu, K., Donaldson, G. P., Shastri, G. G., Ann, P., Ma, L., Nagler, C. R., Ismagilov, R. F., Mazmanian, S. K., & Hsiao, E. Y. (2015) · Cell · doi:10.1016/j.cell.2015.02.047 · Cited by 3,614 · cited 2×
“In germfree mice there is a lower expression of TPH1 and subsequently lower levels of serotonin in colon, feces and serum implicating a regulatory role of the gut microbiome in serotonin concentrations [66].”
BackgroundGut Microbiota Regulation of Tryptophan Metabolism in Health and Disease
Agus, A., Planchais, J., & Sokol, H. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.05.003 · Cited by 3,180 · cited 8×
“Metabolites such as tryptamine (TRP), 3-methylindole (3MI), indole-3-acetaldehyde, IA, indole-3-aldehyde, indole acrylic acid, kynurenine, KA, XA and 5-hydroxyindoleacetic acid (5-HIAA) are ligands for AhR [56,57].”
BackgroundInfluentialMicrobial tryptophan catabolites in health and disease
Roager, H. M., & Licht, T. R. (2018) · Nature Communications · doi:10.1038/s41467-018-05470-4 · Cited by 2,236 · cited 1×
“Administration of antibiotics resulted in a decrease of Bacteroidetes and Clostridia species, both of which are associated with tryptophan metabolism in the gut and they demonstrated that a reduction in these species was related to a decrease in gut-derived tryptophan metabolites [51,118].”
BackgroundYounossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235 · cited 1×
“Non-alcoholic fatty liver disease (NAFLD) affects >25% of the population worldwide [1].”
BackgroundControl of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor
Quintana, F. J., Basso, A. S., Iglesias, A. H., Korn, T., Farez, M. F., Bettelli, E., Caccamo, M., Oukka, M., & Weiner, H. L. (2008) · Nature · doi:10.1038/nature06880 · Cited by 1,865 · cited 1×
“AhR is expressed throughout the body, but highest levels are found in the intestine, lung and skin, and it has been shown to regulate the immune system through several mechanisms [58] such as regulation of the differentiation of Th17 and Treg cells (see Figure 4) [59,60].”
BackgroundA gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites
Dodd, D., Spitzer, M. H., Van Treuren, W., Merrill, B. D., Hryckowian, A. J., Higginbottom, S. K., Le, A., Cowan, T. M., Nolan, G. P., Fischbach, M. A., et al. (2017) · Nature · doi:10.1038/nature24661 · Cited by 1,425 · cited 2×
“Here, the indole pathway is regulated by the gut microbiome and results in different indoles such as indole-3-acetate (IA), indole-3-propionate (IPA) and skatole (3-methylindole) (see Figure 3) [50].”
BackgroundKynurenine pathway of tryptophan metabolism: regulatory and functional aspects
Badawy, A. A.-B. (2017) · International Journal of Tryptophan Research · doi:10.1177/1178646917691938 · Cited by 1,158 · cited 1×
“Once absorbed into the circulation, about 90% tryptophan will be metabolized by IDO1, IDO2 and TDO into N-formylkynurenine [40].”
BackgroundRivera, C. A., Adegboyega, P., van Rooijen, N., Tagalicud, A., Allman, M., & Wallace, M. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.04.019 · Cited by 693 · cited 1×
“LPS binds to toll like receptor 4 (TLR4) activating the innate immune system in the liver, especially Kupffer cells and infiltrating monocytes/macrophages [16,17].”
Background
Cited by
The gut–liver axis and gut microbiota in health and liver disease
Hsu, C. L., & Schnabl, B. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00904-3 · Cited by 737
Gut Microbiota-Derived Tryptophan Metabolites Maintain Gut and Systemic Homeostasis
Su, X., Gao, Y., & Yang, R. (2022) · Cells · doi:10.3390/cells11152296 · Cited by 424
Hou, Y., Li, J., & Ying, S. (2023) · Metabolites · doi:10.3390/metabo13111166 · Cited by 213
“In addition, Trp metabolism by intestinal microbes may have a role in maintaining immune system stability within the body [72].”
BackgroundLeFort, K. R., Rungratanawanich, W., & Song, B.-J. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05061-7 · Cited by 202
“Endotoxemia is also affiliated with mitochondrial dysfunction [25] and systemic inflammation [172] in rodent models of ALD [11, 126, 151, 173] and MASLD [20, 51, 68, 151, 174–178].”
BackgroundTargeting nonalcoholic fatty liver disease via gut microbiome-centered therapies
Koning, M., Herrema, H., Nieuwdorp, M., & Meijnikman, A. S. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2226922 · Cited by 56
“The microbiota can directly convert tryptophan into indole and its derivatives and can enter host metabolic pathways leading to formation of kynurenine or serotonergic compounds.(90,101) Oxindoles, kynurenine-related compounds, and other tryptophan metabolites have been linked to poor outcomes in cirrhosis.”
Background
Metadata
- Authors
- Teunis, C., Nieuwdorp, M., & Hanssen, N.
- Venue
- Metabolites
- Publisher
- MDPI AG
- Published
- 2022-06-02
- Volume
- 12
- Issue
- 6
- Pages
- 514
- ISSN
- 2218-1989 (ISSN-L)
- OpenAlex
- W4281786295
- Cited by
- 113
- References
- 14
- FWCI
- 5.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interactions between Tryptophan Metabolism, the Gut Microbiome and the Immune System as Potential Drivers of Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Diseases. https://app.cochat.ai/papers/10.3390/metabo12060514
- The paper
- Teunis, C., Nieuwdorp, M., & Hanssen, N. (2022). Interactions between Tryptophan Metabolism, the Gut Microbiome and the Immune System as Potential Drivers of Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Diseases. Metabolites. https://doi.org/10.3390/metabo12060514
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.